TickerFacts.

Bioadaptives, Inc. (BDPT): Revenue

Annual figures by period end, from SEC filings.

$18.3K
Year ended 2025-12-31
$25.6K
Trailing 12 months to 2026-06-30
+2.1%
3-year compound annual growth
+2.3%
5-year compound annual growth
$28.6K2019-12-31: $9.9K2020-12-31: $16.3K2021-12-31: $19.8K2022-12-31: $17.2K2023-12-31: $28.6K2024-12-31: $12.7K2025-12-31: $18.3K$18.3K
2019-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$18.3K+44.3%2026-04-14, From 2025-01-01
2024-12-31$12.7K-55.6%2026-04-14, From 2024-01-01
2023-12-31$28.6K+66.3%2025-04-15, From 2023-01-01
2022-12-31$17.2K-13.1%2024-04-10, From 2022-01-01
2021-12-31$19.8K+21.1%2023-03-31, From 2021-01-01
2020-12-31$16.3K+64.4%2022-03-31, From 2020-01-01
2019-12-31$9.9Kn/a2021-03-30, From 2019-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Bioadaptives, Inc. (BDPT)2025-12-31$18.3K+44.3%
PRF Technologies Ltd. (PRFX)2025-12-31$17.0Kn/a
Skinvisible, Inc. (SKVI)2025-12-31$20.0K0.0%
Jupiter Neurosciences, Inc. (JUNS)2025-12-31$21.8Kn/a
Talphera, Inc. (TLPH)2025-12-31$28.0Kn/a
Impact Biomedical Inc. (IBO)2025-12-31$32.0Kn/a
Lyell Immunopharma, Inc. (LYEL)2025-12-31$36.0K-41.0%
Neonc Technologies Holdings, Inc. (NTHI)2025-12-31$40.0K-51.8%
Altimmune, Inc. (ALT)2025-12-31$41.0K+105.0%

Compare BDPT, PRFX, SKVI, JUNS side by side · Screen every company in Pharmaceutical Preparations ↗